Medications for PTSD Beyond Antidepressants
For PTSD-associated nightmares specifically, prazosin is the most strongly recommended non-antidepressant medication, while for broader PTSD symptoms, atypical antipsychotics (risperidone, aripiprazole, olanzapine) represent the best-supported non-antidepressant pharmacologic options.
Primary Non-Antidepressant Options
Prazosin (Alpha-1 Adrenergic Antagonist)
Prazosin is recommended (Level A evidence) specifically for PTSD-associated nightmares 1. This is the strongest non-antidepressant recommendation in the guidelines.
- Dosing approach: Start at 1 mg at bedtime, increase by 1-2 mg every few days until effective
- Typical effective dose: Average ~3 mg, though range is 1-13 mg/day (higher doses often needed for combat veterans)
- Evidence: Three Level 1 placebo-controlled trials showed statistically significant reduction in trauma-related nightmares (CAPS nightmare scores improved from 4.8-6.9 to 3.2-3.6)
- Key monitoring: Watch for orthostatic hypotension
- Mechanism: Reduces elevated CNS noradrenergic activity that disrupts REM sleep and contributes to nightmares and hyperarousal 1
Atypical Antipsychotics
These represent the next tier of non-antidepressant options, particularly as augmentation therapy 2:
Risperidone has the strongest evidence among antipsychotics 3:
- Demonstrated moderate-to-high efficacy in treating PTSD-related nightmares
- Dosing: 0.5-3 mg/day (average 2.3 mg)
- One 12-week trial showed significant decrease in nightmare frequency (38% to 19% of nights)
- Works via alpha-1 and alpha-2 noradrenergic antagonism 2
Olanzapine and Aripiprazole may also be used 2:
- Olanzapine: 10-20 mg/day, increases slow-wave sleep and reduces REM
- Limited but positive case series data
- Consider as augmentation when SSRIs/SNRIs provide insufficient response
Secondary Non-Antidepressant Options
Clonidine (Alpha-2 Agonist)
- May be considered (Level C) for PTSD-associated nightmares 1
- Dosing: 0.2-0.6 mg in divided doses
- Shares therapeutic rationale with prazosin but less rigorously studied
- Monitor for postural hypotension
- Has been used for over 20 years in severely traumatized refugees, though lacks randomized controlled trials 1
Additional Agents with Lower-Grade Evidence (Level C)
The following may be considered but have sparse data 1:
For nightmares/sleep disturbances:
- Trazodone: 25-600 mg (mean 212 mg); 72% reported decreased nightmares in one study, but 60% experienced side effects (sedation, dizziness, priapism)
- Triazolam and nitrazepam: Benzodiazepine receptor agonists for nightmare disorder specifically 2
Other options:
- Topiramate: Anticonvulsant with some supporting data
- Gabapentin: May help with hyperarousal symptoms
- Cyproheptadine: Antihistamine with antiserotonergic properties
- Phenelzine: MAOI (requires dietary restrictions)
- Nabilone: Synthetic cannabinoid (limited evidence)
Important Contraindications
The following are NOT recommended 2:
- Clonazepam: Specifically not recommended for nightmare disorder
- Venlafaxine: Not recommended for nightmare disorder (though it IS recommended as first-line for general PTSD as an SNRI)
- Benzodiazepines generally: The 2024 VA/DoD guideline recommends AGAINST benzodiazepines, cannabis, or cannabis-derived products for PTSD 4
Clinical Algorithm for Non-Antidepressant Selection
Step 1: If nightmares are the predominant symptom → Start prazosin
Step 2: If inadequate response to SSRIs/SNRIs for general PTSD symptoms → Add risperidone (strongest augmentation evidence)
Step 3: If nightmares persist despite prazosin → Consider adding trazodone at bedtime (though monitor for side effects)
Step 4: For treatment-refractory cases → Consider olanzapine or aripiprazole as augmentation, or trial topiramate or gabapentin
Step 5: If insomnia without nightmares → Clonidine may be considered, though avoid benzodiazepines
Critical Caveats
- Most studies evaluated these medications as augmentation to ongoing psychotherapy and other psychotropics, not as monotherapy 1
- Psychotherapy (particularly trauma-focused CBT) remains first-line treatment and should not be replaced by pharmacotherapy alone 4
- Evidence for non-antidepressant medications is generally weaker than for SSRIs/SNRIs (only sertraline and paroxetine are FDA-approved for PTSD) 4, 5
- Many promising agents have failed in late-stage trials due to high placebo response rates and patient heterogeneity 6
- Avoid the temptation to use benzodiazepines despite their anxiolytic properties—they may actually increase PTSD risk and are explicitly not recommended 4, 5